Do you want more affordable medicines?  If so, you should know that the legal brief filed to the Supreme Court by the Trump administration arguing that the entire Affordable Care Act (ACA) be overturned as unconstitutional, if successful, would also eliminate the Biologics Price Competition and Innovation Act (BPCIA).

The BPCIA is the part of the ACA that allows the Food and Drug Administration to approve biosimilar drugs (often called generic biologics). Should the Supreme Court agree with the Trump administration’s brief, the FDA will no longer be allowed to approve new, less expensive biosimilars and, possibly, the FDA’s approval of those products now on the market will be retracted.

Keith WebberRockville

The writer is a former acting director of the Food and Drug Administration’s Office of Biotechnology Products and Office of Generic Drugs.